This contrast with the recommendation for closely monitoring serum PSA level after the nadir following one year of 5-ARI treatment, and stablishing PCa suspicion based on a confirmed increase of serum PSA levels higher than 0.3 ng/ml [19]. The gene discussed is KLK3; the disease is posterior cortical atrophy.